Clinical trials: CIN 1
Cervical Intraepithelial Neoplasia Grade 1, Human Papillomavirus 16 Infection
Phase I/II Trial of Electroporation-Delivered pBI-4 Vaccine (TriGrid™ PVX4) for Treatment of Women With HPV16-Positive CIN1 or Persistent Infection
The purpose of this study is to evaluate the safety, efficacy, and tolerability of pBI-4, an investigational therapeutic DNA vaccine, in treating adult women with Human Papillomavirus type 16 (HPV16)-positive Grade 1 cervical…
- Trial name
- NCT07809997
- Testing
- pBI-4 Vaccine
- Where
- 2 sites in Taiwan
- Volunteers
- 94 people
- Sponsor
- Chang Gung Memorial Hospital
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP)…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- REVEAL 1 (NCT03185013)
- Testing
- VGX-3100, Electroporation (EP)
- Where
- 60 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Cancer, Precancerous Condition
Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia in Patients With An Abnormal Pap Smear
RATIONALE: Diagnostic procedures, such as digital colposcopy, may help doctors find and diagnose cervical intraepithelial neoplasia.
- Trial name
- NCT00610662
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Human Papilloma Virus, Dysplasia
Phase II Evaluation of AHCC for the Eradication of HPV Infections
This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary outcome of this trial is achieving durable eradication persistent high risk HPV infection determined by HPV negative test results…
- Conditions
- Human Papilloma Virus, Dysplasia, CIN1, CIN2
- Trial name
- AHCC4HPV (NCT02405533)
- Testing
- AHCC 3 grams once a day
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Atypical Squamous Cell of Undetermined Significance, ASC-US
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
This study compares the efficacy of cytology (Pap smear) with the molecular screening in their ability to detect reactive cellular changes in the cervix among an open population
- Conditions
- Atypical Squamous Cell of Undetermined Significance, ASC-US, Atypical Glandular Cells of Uncertain Significance, AGUS
- Trial name
- NCT07211204
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Cervical Intraepithelial Neoplasia
Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)
The purpose of this study is to determine the efficacy and the safety of BLS-ILB-E710c for the the fertile women with Cervical Intraepithelial Neoplasia (CIN3).
- Trial name
- NCT02195089
- Testing
- BLS_ILS_E710c 500mg, BLS_ILB_710c 1000mg, BLS_ILS_E710c 1500mg
- Where
- 5 sites in South Korea
- Volunteers
- 19 people
- Sponsor
- BioLeaders Corporation
Gastroenteritis Norovirus
Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)
This is phase I, double blind, placebo-controlled safety and infectivity study of experimental human Norovirus genogroup GII.4 administered to healthy adults 18-49 years of age.
- Trial name
- NCT02337842
- Testing
- Norovirus GII.4 Challenge Pool CIN-1
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Cancer, Precancerous Condition
Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- SAGE (NCT00629577)
- Testing
- microarray analysis, flow cytometry, biopsy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Cervical Cancer, Precancerous Condition
Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical…
- Trial name
- NCT00031759
- Testing
- imiquimod, Ablative or excisional therapy
- Where
- 8 sites in United States
- Volunteers
- 57 people
- Sponsor
- Alliance for Clinical Trials in Oncology
HPV Infection, HPV-Related Cervical Carcinoma
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16.
- Trial name
- NCT05829629
- Testing
- FluBHPVE6E7
- Where
- Slovakia
- Volunteers
- 20 people
- Sponsor
- BlueSky Immunotherapies GmbH
Cervical Intraepithelial Neoplasia
Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the efficacy and the safety of PGA(Poly-gamma Glutamic Acid) for the the fertile women with Cervical Intraepithelial Neoplasia (CIN1).
- Trial name
- PGA (NCT01826045)
- Testing
- Poly-gamma Glutamic Acid
- Where
- 7 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- BioLeaders Corporation
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Cervical Intraepithelial Neoplasia II
Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer
The purpose of this study is to determine whether Insulin-like Growth Factor II is elevated sufficiently to detect Cervical Intraepithelial Neoplasia II (CIN II), Cervical Intraepithelial Neoplasia III (CIN III), and cervical…
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia II, Cervical Intraepithelial Neoplasia III
- Trial name
- NCT01371695
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Onconix, Inc
Cervical Intraepithelial Neoplasia
Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1
The study will examine the effect of HAL vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.
- Trial name
- NCT00708942
- Testing
- Hexaminolevulinate (HAL)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Photocure
CIN1, Trichloroacetic Acid
Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test
To evaluate the efficacy of topical 95% TCA in the treatment of CIN 1 or less after low grade abnormality of screening test
- Trial name
- NCT06188104
- Testing
- Trichloroacetic acid
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Human Papillomavirus Infection, Cervical Cancer
Primary Cervical Cancer Screening by Self-sampling HPV Test
Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider…
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
- Trial name
- PREVENT (NCT05613283)
- Where
- 6 sites in China
- Volunteers
- 17,875 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS)
Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer
This study compares how effective is the molecular screening (a blood test) using Pap smear as reference, that is, a comparison of these tests abilities to detect precursor lesions and cervical cancer among women of an open…
- Conditions
- I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS), III) Cervical Intraepithelial Neoplasia (CIN), CIN-1, CIN-2, CIN-3, IV) Low-grade Squamous Intraepithelial Lesion (LSIL)
- Trial name
- NCT07480902
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
HIV (Human Immunodeficiency Virus), HPV
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general…
- Conditions
- HIV (Human Immunodeficiency Virus), HPV, Cervical Precancer
- Trial name
- NCT07468695
- Testing
- Thermal ablation (TA) with 1 probe, Thermal ablation (TA) with 2 probes
- Where
- Kenya
- Volunteers
- 300 people
- Sponsor
- Fred Hutchinson Cancer Center
Norovirus Infections
Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)
The purpose of this study is to determine a suitable dose of the human norovirus GII.4 challenge pool(CIN-1;031693) that induces illness in approximately 50% of susceptible subjects that would be useful for evaluation of vaccines…
- Trial name
- CIN-002 (NCT01435811)
- Testing
- Norovirus challenge pool (GII.4, CIN-1)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 1
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
This randomized phase II trial is studying green tea extract to see how well it works compared to a placebo in preventing cervical cancer in patients with human papillomavirus and low-grade cervical intraepithelial neoplasia.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 1, Human Papilloma Virus Infection
- Trial name
- NCT00303823
- Testing
- defined green tea catechin extract, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)